Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.

PURPOSE Seminal vesicle invasion (SVI) in a radical prostatectomy (RRP) specimen is associated with a guarded prognosis. We evaluated patients with SVI treated in the pre-prostate specific antigen (PSA) (1983 to 1991) and PSA (1992 to 2003) eras. MATERIALS AND METHODS Of patients with prostate cancer treated with RRP from January 1983 through March 2002, 220 with SVI were evaluated, including 67 in the pre-PSA era and 153 in the PSA era. Postoperative PSA greater than 0.2 ng/ml was considered biochemical evidence of cancer progression. Survival rates were compared using Kaplan-Meier estimates to calculate progression-free, cancer specific and all cause survival. Multivariate Cox proportional hazard models were used to correlate variables with disease progression. RESULTS The incidence of SVI in the PSA era was lower than in the pre-PSA era (6.0% vs 10.2%, p = 0.001). To date 124 patients (56%) have had evidence of cancer progression. The 4 and 7-year progression-free, cancer specific and all cause survival rates were significantly higher in men with SVI in the PSA era (p = 0.02). PSA at diagnosis, cancerous surgical margins and higher Gleason score were significantly associated with progression. Neither adjuvant nor salvage radiotherapy appeared to confer a significant progression-free survival benefit. CONCLUSIONS The incidence of SVI has decreased in the PSA era. Progression-free, cancer specific and all cause survival rates following RRP in patients with SVI have improved in the PSA era. This may reflect earlier detection in this pathological tumor stage and more favorable prognostic factors associated with PSA screening. Adjuvant radiotherapy does not appear to confer any therapeutic benefit. Salvage radiotherapy can lead to durable PSA regressions in a small percent of men, although no long-term survival advantage can be proved.

[1]  E. B. Butler,et al.  Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. , 2004, JAMA.

[2]  C. Roehrborn,et al.  Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. , 2003, Urology.

[3]  E. Venkatraman,et al.  Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Campbell,et al.  Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. , 2002, International journal of radiation oncology, biology, physics.

[5]  A. Zietman,et al.  Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. , 2002, Urology.

[6]  M. Benson,et al.  Postprostatectomy Salvage Radiation Therapy for Prostate Cancer: Impact of Pathological and Biochemical Variables and Prostate Fossa Biopsy , 2002, Cancer journal.

[7]  H. Frierson,et al.  Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years , 2002, Cancer.

[8]  D. Kuban,et al.  Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[9]  A. Partin,et al.  Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy , 2000, Cancer.

[10]  P. Carroll,et al.  Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. , 1999, Urology.

[11]  W. Catalona,et al.  Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. , 1999, The Journal of urology.

[12]  A. Renshaw,et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, JAMA.

[13]  M. Banerjee,et al.  Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. , 1998, The Journal of urology.

[14]  R. Valicenti,et al.  Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma , 1998, Cancer.

[15]  W. Hop,et al.  Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. , 1997, British journal of urology.

[16]  S. Schild,et al.  The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. , 1996, International journal of radiation oncology, biology, physics.

[17]  P. Scardino,et al.  The Mechanisms and Prognostic Significance of Seminal Vesicle Involvement by Prostate Cancer , 1993, The American journal of surgical pathology.

[18]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[19]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[20]  M. Soloway,et al.  Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. , 2003, The Journal of urology.

[21]  A. D'Amico,et al.  5 year biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer , 1998 .